-
Development Pipeline
Development-stage programs in gout, cancer and HIV -
Gout
First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout -
Cancer
BAY 86-9766 (formerly known as RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, is being developed under a global license agreement with Bayer Healthcare AG -
HIV
First and next-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of HIV
Scientific Publications
Scientific publications, posters and presentations relating to Ardea Biosciences’ proprietary research programs or research collaborations with other biotechnology or pharmaceutical companies will be posted once they are available.
Company Presentations |
|
 |
Ardea Company Update, January 9, 2012 |
Latest News
- 06 Feb 2012 Ardea Biosciences Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
- 01 Feb 2012 Ardea Biosciences Prices Public Offering of Common Stock
- 31 Jan 2012 Ardea Biosciences Announces Proposed Public Offering of Common Stock
Upcoming Events
There are currently no upcoming events scheduled.